Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model

Seahyoung Lee, Hyun Joung Lim, Hyun Young Park, Kuy Sook Lee, Jin Hee Park, Yangsoo Jang

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Berberine, an alkaloid isolated from Chinese medicinal herbs, long been known for its anti-microbial activity and used to treat various infectious disorders in traditional Chinese medicine. In the present study, we have tested the hypothesis that berberine could inhibit vascular smooth muscle cell (VSMC) proliferation as it did in endothelial cells or cancer cells. Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway. Furthermore, we have examined its effect in vivo using a rat carotid artery injury model. A 28 days of chronic berberine treatment using an osmotic pump (100 μg kg-1 d-1, 2 weeks before and 2 weeks after the injury) improved neointima formation. The Neointima/Media ratio for control group and berberine treated group were 1.14 ± 0.11 and 0.85 ± 0.06 (p < 0.05), respectively, and the reduction was approximately 25%. The result of the present study suggests a possibility of berberine being a potent agent to control restenosis after balloon angioplasty and warrants further study to gain a more complete understanding of its underlying mechanisms at a cellular level.

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalAtherosclerosis
Volume186
Issue number1
DOIs
Publication statusPublished - 2006 May 1

Fingerprint

Berberine
Neointima
Vascular Smooth Muscle
Smooth Muscle Myocytes
Cell Movement
Cell Proliferation
Wounds and Injuries
Berberine Alkaloids
Carotid Artery Injuries
Balloon Angioplasty
MAP Kinase Signaling System
Chinese Traditional Medicine
Medicinal Plants
Epidermal Growth Factor
Angiotensin II
Heparin
Intercellular Signaling Peptides and Proteins
Endothelial Cells
In Vitro Techniques
Control Groups

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{60870c686f794c78bfdfe353faed017e,
title = "Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model",
abstract = "Berberine, an alkaloid isolated from Chinese medicinal herbs, long been known for its anti-microbial activity and used to treat various infectious disorders in traditional Chinese medicine. In the present study, we have tested the hypothesis that berberine could inhibit vascular smooth muscle cell (VSMC) proliferation as it did in endothelial cells or cancer cells. Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway. Furthermore, we have examined its effect in vivo using a rat carotid artery injury model. A 28 days of chronic berberine treatment using an osmotic pump (100 μg kg-1 d-1, 2 weeks before and 2 weeks after the injury) improved neointima formation. The Neointima/Media ratio for control group and berberine treated group were 1.14 ± 0.11 and 0.85 ± 0.06 (p < 0.05), respectively, and the reduction was approximately 25{\%}. The result of the present study suggests a possibility of berberine being a potent agent to control restenosis after balloon angioplasty and warrants further study to gain a more complete understanding of its underlying mechanisms at a cellular level.",
author = "Seahyoung Lee and Lim, {Hyun Joung} and Park, {Hyun Young} and Lee, {Kuy Sook} and Park, {Jin Hee} and Yangsoo Jang",
year = "2006",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2005.06.048",
language = "English",
volume = "186",
pages = "29--37",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. / Lee, Seahyoung; Lim, Hyun Joung; Park, Hyun Young; Lee, Kuy Sook; Park, Jin Hee; Jang, Yangsoo.

In: Atherosclerosis, Vol. 186, No. 1, 01.05.2006, p. 29-37.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model

AU - Lee, Seahyoung

AU - Lim, Hyun Joung

AU - Park, Hyun Young

AU - Lee, Kuy Sook

AU - Park, Jin Hee

AU - Jang, Yangsoo

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Berberine, an alkaloid isolated from Chinese medicinal herbs, long been known for its anti-microbial activity and used to treat various infectious disorders in traditional Chinese medicine. In the present study, we have tested the hypothesis that berberine could inhibit vascular smooth muscle cell (VSMC) proliferation as it did in endothelial cells or cancer cells. Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway. Furthermore, we have examined its effect in vivo using a rat carotid artery injury model. A 28 days of chronic berberine treatment using an osmotic pump (100 μg kg-1 d-1, 2 weeks before and 2 weeks after the injury) improved neointima formation. The Neointima/Media ratio for control group and berberine treated group were 1.14 ± 0.11 and 0.85 ± 0.06 (p < 0.05), respectively, and the reduction was approximately 25%. The result of the present study suggests a possibility of berberine being a potent agent to control restenosis after balloon angioplasty and warrants further study to gain a more complete understanding of its underlying mechanisms at a cellular level.

AB - Berberine, an alkaloid isolated from Chinese medicinal herbs, long been known for its anti-microbial activity and used to treat various infectious disorders in traditional Chinese medicine. In the present study, we have tested the hypothesis that berberine could inhibit vascular smooth muscle cell (VSMC) proliferation as it did in endothelial cells or cancer cells. Our results show that berberine significantly inhibits growth factor, mainly angiotensin II (AngII) and heparin binding epidermal growth factor (HB-EGF), induced VSMC proliferation and migration in vitro, and this effect is achieved by delaying or partially suppressing activation of Akt pathway rather than ERK pathway. Furthermore, we have examined its effect in vivo using a rat carotid artery injury model. A 28 days of chronic berberine treatment using an osmotic pump (100 μg kg-1 d-1, 2 weeks before and 2 weeks after the injury) improved neointima formation. The Neointima/Media ratio for control group and berberine treated group were 1.14 ± 0.11 and 0.85 ± 0.06 (p < 0.05), respectively, and the reduction was approximately 25%. The result of the present study suggests a possibility of berberine being a potent agent to control restenosis after balloon angioplasty and warrants further study to gain a more complete understanding of its underlying mechanisms at a cellular level.

UR - http://www.scopus.com/inward/record.url?scp=33646479753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646479753&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2005.06.048

DO - 10.1016/j.atherosclerosis.2005.06.048

M3 - Article

C2 - 16098530

AN - SCOPUS:33646479753

VL - 186

SP - 29

EP - 37

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -